Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age.

Papasavvas E, Azzoni L, Foulkes A, Violari A, Cotton MF, Pistilli M, Reynolds G, Yin X, Glencross DK, Stevens WS, McIntyre JA, Montaner LJ.

Pediatr Infect Dis J. 2011 Oct;30(10):877-82. doi: 10.1097/INF.0b013e31821d141e.

2.

Increased gut microbial translocation in HIV-infected children persists in virologic responders and virologic failures after antiretroviral therapy.

Pilakka-Kanthikeel S, Huang S, Fenton T, Borkowsky W, Cunningham CK, Pahwa S.

Pediatr Infect Dis J. 2012 Jun;31(6):583-91. doi: 10.1097/INF.0b013e31824da0f5.

3.

Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.

Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, Josipovic D, Liberty A, Lazarus E, Innes S, van Rensburg AJ, Pelser W, Truter H, Madhi SA, Handelsman E, Jean-Philippe P, McIntyre JA, Gibb DM, Babiker AG; CHER Study Team.

Lancet. 2013 Nov 9;382(9904):1555-63. doi: 10.1016/S0140-6736(13)61409-9.

4.

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ.

AIDS. 2009 Jan 28;23(3):369-75. doi: 10.1097/QAD.0b013e32831e9c76.

5.

Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.

Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, Sleasman JW, Goodenow MM.

AIDS. 2010 Jun 1;24(9):1281-90. doi: 10.1097/QAD.0b013e328339e228.

6.

Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.

Nyström J, Stenkvist J, Häggblom A, Weiland O, Nowak P.

PLoS One. 2015 Mar 18;10(3):e0118643. doi: 10.1371/journal.pone.0118643. eCollection 2015.

7.

Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.

Abad-Fernández M, Vallejo A, Hernández-Novoa B, Díaz L, Gutiérrez C, Madrid N, Muñoz MA, Moreno S.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):149-53. doi: 10.1097/QAI.0b013e31829a2f12.

PMID:
24047967
8.

Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects.

Toossi Z, Funderburg NT, Sirdeshmuk S, Whalen CC, Nanteza MW, Johnson DF, Mayanja-Kizza H, Hirsch CS.

J Infect Dis. 2013 Jun 15;207(12):1841-9. doi: 10.1093/infdis/jit092. Epub 2013 Mar 11.

9.

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.

Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub TE, Davenport M, Crowe S, Elliott J, Hoy J, Fairley C, Stewart G, Cameron P, Lewin SR.

J Infect Dis. 2010 Oct 15;202(8):1254-64. doi: 10.1086/656369.

PMID:
20812848
10.

Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy.

Vesterbacka J, Barqasho B, Häggblom A, Nowak P.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):830-6. doi: 10.1089/AID.2014.0366. Epub 2015 Jun 15.

PMID:
26059763
11.

Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.

Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL, Wilson CC; A5286 Team.

J Infect Dis. 2015 Mar 1;211(5):780-90. doi: 10.1093/infdis/jiu515. Epub 2014 Sep 11.

12.

Impact of HIV Infection and Anti-Retroviral Therapy on the Immune Profile of and Microbial Translocation in HIV-Infected Children in Vietnam.

Bi X, Ishizaki A, Nguyen LV, Matsuda K, Pham HV, Phan CT, Ogata K, Giang TT, Phung TT, Nguyen TT, Tokoro M, Pham AN, Khu DT, Ichimura H.

Int J Mol Sci. 2016 Aug 2;17(8). pii: E1245. doi: 10.3390/ijms17081245.

13.

Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.

Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS.

J Infect Dis. 2012 Nov 15;206(10):1558-67. doi: 10.1093/infdis/jis545. Epub 2012 Oct 12.

14.

Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS).

Viladés C, Escoté X, López-Dupla M, Martinez E, Domingo P, Asensi V, Leal M, Peraire J, Inza MI, Arnedo M, Gutiérrez M, Valle-Garay E, Ferrando-Martinez S, Olona M, Alba V, Sirvent JJ, Gatell JM, Vidal F; HALS Study Group.

J Antimicrob Chemother. 2014 Jun;69(6):1653-9. doi: 10.1093/jac/dku032. Epub 2014 Feb 16.

PMID:
24535275
15.

Markers of microbial translocation predict hypertension in HIV-infected individuals.

Manner IW, Baekken M, Kvale D, Oektedalen O, Pedersen M, Nielsen SD, Nowak P, Os I, Trøseid M.

HIV Med. 2013 Jul;14(6):354-61. doi: 10.1111/hiv.12015. Epub 2013 Jan 17.

16.

A 12 week longitudinal study of microbial translocation and systemic inflammation in undernourished HIV-infected Zambians initiating antiretroviral therapy.

Canipe A, Chidumayo T, Blevins M, Bestawros M, Bala J, Kelly P, Filteau S, Shepherd BE, Heimburger DC, Koethe JR.

BMC Infect Dis. 2014 Sep 29;14:521. doi: 10.1186/1471-2334-14-521.

17.

Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study.

Puthanakit T, Ananworanich J, Vonthanak S, Kosalaraksa P, Hansudewechakul R, van der Lugt J, Kerr SJ, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Vibol U, Pruksakaew K, Suwarnlerk T, Apornpong T, Ratanadilok K, Paul R, Mofenson LM, Fox L, Valcour V, Brouwers P, Ruxrungtham K; PREDICT Study Group.

Pediatr Infect Dis J. 2013 May;32(5):501-8. doi: 10.1097/INF.0b013e31827fb19d.

18.

HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS.

d'Ettorre G, Paiardini M, Zaffiri L, Andreotti M, Ceccarelli G, Rizza C, Indinnimeo M, Vella S, Mastroianni CM, Silvestri G, Vullo V.

Curr HIV Res. 2011 Apr;9(3):148-53.

PMID:
21457131
19.

Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.

Bukh AR, Melchjorsen J, Offersen R, Jensen JM, Toft L, Støvring H, Ostergaard L, Tolstrup M, Søgaard OS.

PLoS One. 2011;6(6):e21275. doi: 10.1371/journal.pone.0021275. Epub 2011 Jun 24.

20.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235

Supplemental Content

Support Center